Idalopirdine

Idalopirdine is a pharmaceutical drug that was under development for the treatment of Alzheimer's disease. It was developed by Lundbeck and Otsuka Pharmaceutical but failed in late-stage clinical trials.

History[edit | edit source]

Idalopirdine was initially developed by Lundbeck and Otsuka Pharmaceutical. The drug entered Phase III clinical trials in 2014. However, in 2018, it was announced that the drug had failed in three separate Phase III clinical trials. As a result, development of the drug was discontinued.

Mechanism of Action[edit | edit source]

Idalopirdine is a 5-HT6 receptor antagonist. The 5-HT6 receptor is a subtype of the 5-HT receptor that binds the neurotransmitter serotonin. It is thought that by blocking this receptor, idalopirdine could enhance the release of acetylcholine in the brain, thereby improving cognitive function.

Clinical Trials[edit | edit source]

Idalopirdine was tested in three separate Phase III clinical trials, all of which failed to meet their primary endpoints. The trials were designed to test the efficacy of the drug in improving cognitive function in patients with Alzheimer's disease. The primary endpoint was a change in the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-Cog) score.

Discontinuation[edit | edit source]

Following the failure of the Phase III trials, Lundbeck and Otsuka announced in 2018 that they would discontinue the development of idalopirdine. The decision was based on an assessment of the trial data, which showed that the drug did not have a sufficient effect on cognitive function in patients with Alzheimer's disease.

See Also[edit | edit source]

Idalopirdine Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.